156 related articles for article (PubMed ID: 19009294)
1. Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients.
Litzinger MT; Foon KA; Sabzevari H; Tsang KY; Schlom J; Palena C
Cancer Immunol Immunother; 2009 Jun; 58(6):955-65. PubMed ID: 19009294
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells.
Litzinger MT; Foon KA; Tsang KY; Schlom J; Palena C
Leuk Res; 2010 Oct; 34(10):1351-7. PubMed ID: 20122733
[TBL] [Abstract][Full Text] [Related]
3. Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.
Palena C; Foon KA; Panicali D; Yafal AG; Chinsangaram J; Hodge JW; Schlom J; Tsang KY
Blood; 2005 Nov; 106(10):3515-23. PubMed ID: 16081691
[TBL] [Abstract][Full Text] [Related]
4. Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules.
Hodge JW; Grosenbach DW; Rad AN; Giuliano M; Sabzevari H; Schlom J
Vaccine; 2001 May; 19(25-26):3552-67. PubMed ID: 11348723
[TBL] [Abstract][Full Text] [Related]
5. Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3).
Shankar P; Schlom J; Hodge JW
Vaccine; 2001 Dec; 20(5-6):744-55. PubMed ID: 11738738
[TBL] [Abstract][Full Text] [Related]
6. T Cell Activation Pathways: B7, LFA-3, and ICAM-1 Shape Unique T Cell Profiles.
Wingren AG; Parra E; Varga M; Kalland T; Sjogren HO; Hedlund G; Dohlsten M
Crit Rev Immunol; 2017; 37(2-6):463-481. PubMed ID: 29773030
[TBL] [Abstract][Full Text] [Related]
7. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.
Kudo-Saito C; Hodge JW; Kwak H; Kim-Schulze S; Schlom J; Kaufman HL
Vaccine; 2006 Jun; 24(23):4975-86. PubMed ID: 16621183
[TBL] [Abstract][Full Text] [Related]
8. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.
Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M
Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672
[TBL] [Abstract][Full Text] [Related]
9. Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.
Heery CR; Palena C; McMahon S; Donahue RN; Lepone LM; Grenga I; Dirmeier U; Cordes L; Marté J; Dahut W; Singh H; Madan RA; Fernando RI; Hamilton DH; Schlom J; Gulley JL
Clin Cancer Res; 2017 Nov; 23(22):6833-6845. PubMed ID: 28855356
[No Abstract] [Full Text] [Related]
10. Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8+ T cells.
Yang S; Schlom J
Cancer Immunol Immunother; 2009 Apr; 58(4):503-15. PubMed ID: 18690438
[TBL] [Abstract][Full Text] [Related]
11. Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors.
Rad AN; Schlom J; Hodge JW
Crit Rev Oncol Hematol; 2001; 39(1-2):43-57. PubMed ID: 11418301
[TBL] [Abstract][Full Text] [Related]
12. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules.
Briones J; Timmerman JM; Panicalli DL; Levy R
J Natl Cancer Inst; 2003 Apr; 95(7):548-55. PubMed ID: 12671023
[TBL] [Abstract][Full Text] [Related]
13. A triad of costimulatory molecules synergize to amplify T-cell activation in both vector-based and vector-infected dendritic cell vaccines.
Schlom J; Sabzevari H; Grosenbach DW; Hodge JW
Artif Cells Blood Substit Immobil Biotechnol; 2003 May; 31(2):193-228. PubMed ID: 12751840
[TBL] [Abstract][Full Text] [Related]
14. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules.
Hodge JW; Rad AN; Grosenbach DW; Sabzevari H; Yafal AG; Gritz L; Schlom J
J Natl Cancer Inst; 2000 Aug; 92(15):1228-39. PubMed ID: 10922408
[TBL] [Abstract][Full Text] [Related]
15. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.
Zhu M; Terasawa H; Gulley J; Panicali D; Arlen P; Schlom J; Tsang KY
Cancer Res; 2001 May; 61(9):3725-34. PubMed ID: 11325845
[TBL] [Abstract][Full Text] [Related]
16. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
[TBL] [Abstract][Full Text] [Related]
17. Human naive and memory T-helper cells display distinct adhesion properties to ICAM-1, LFA-3 and B7 molecules.
Parra E; Wingren AG; Hedlund G; Sjögren HO; Kalland T; Sansom D; Dohlsten M
Scand J Immunol; 1993 Dec; 38(6):508-14. PubMed ID: 7504826
[TBL] [Abstract][Full Text] [Related]
18. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
19. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.
Takahashi S; Rousseau RF; Yotnda P; Mei Z; Dotti G; Rill D; Hurwitz R; Marini F; Andreeff M; Brenner MK
Hum Gene Ther; 2001 Apr; 12(6):659-70. PubMed ID: 11426465
[TBL] [Abstract][Full Text] [Related]
20. Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells.
Palena C; Zhu M; Schlom J; Tsang KY
Blood; 2004 Jul; 104(1):192-9. PubMed ID: 15010371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
